The efficiency of the mometasone furoate in profilaxis of the asphyxia attacks at patients suffering from the seasonal asthma caused by sensitization to the pollen of plants

E. Ditiatkovskaya, J. Bendetskaya, O. Koretskya, V. Ditiatkovsky (Dnipropetrovsk, Ukraine)

Source: Annual Congress 2007 - Novel issues in the treatment and control of asthma
Session: Novel issues in the treatment and control of asthma
Session type: Thematic Poster Session
Number: 564
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Ditiatkovskaya, J. Bendetskaya, O. Koretskya, V. Ditiatkovsky (Dnipropetrovsk, Ukraine). The efficiency of the mometasone furoate in profilaxis of the asphyxia attacks at patients suffering from the seasonal asthma caused by sensitization to the pollen of plants. Eur Respir J 2007; 30: Suppl. 51, 564

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion
Source: Eur Respir J 2006; 28: Suppl. 50, 664s
Year: 2006

Mometasone furoate nasal spray compared with loradatine in school children with seasonal allergic rhinitis
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Budesonide nasal spray alone or in combination with cetirizine in patients with severe seasonal allergic rhinitis and asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 45s
Year: 2002

Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function
Source: Eur Respir J 2008; 32: 989-996
Year: 2008



Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS
Source: Eur Respir J 2003; 22: Suppl. 45, 4s
Year: 2003

Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Mometasone furoate is safe and effective for long-term use in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 148s
Year: 2001

Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

A comparison of oral loratadine and fluticasone propionate aqueous nasal spray plus oral loratadine in the treatment of atopic cough associated with seasonal allergic rhinitis (SAR)
Source: Eur Respir J 2005; 26: Suppl. 49, 136s
Year: 2005

Mometasone furoate 400 μg once daily is more efficacious than budesonide 400 μg once daily in improving asthma symptoms in patients with moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

A comparison of the efficacy of beclomethasone dipropionate (BDP) and fluticasone propionate (FP) aqueous nasal spray on symptoms and quality of life in perennial allergic rhinitis
Source: Eur Respir J 2003; 22: Suppl. 45, 110s
Year: 2003

Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Safety and efficacy of momethason furoate for usage in school children with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 290s
Year: 2003

Reduction in oral corticosteroid use with mometasone furoate DPI improves health-related quality of life in patients with severe persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 395s
Year: 2002

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001